Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Doxorubicin
Drug: Lipiodol

First Posted Date: 2022-03-22

Last Posted Date: 2023-07-28

Lead Sponsor: Rehab Werida

Target Recruit Count: 107

Registration Number: NCT05291338

Locations: 🇪🇬
Ain Shams University hepatoma group, EL Demerdash Hospital, Cairo, Egypt., Cairo, Egypt

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Not Applicable

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: doxorubicin
Drug: epirubicin
Drug: pirarubicin
Drug: cyclophosphamide
Drug: albumin-bound paclitaxel
Drug: paclitaxel
Drug: docetaxel

First Posted Date: 2022-03-18

Last Posted Date: 2022-03-31

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 500

Registration Number: NCT05287308

Locations: 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: HER2-negative Breast Cancer
Advanced Solid Tumor

Interventions: Drug: ADG106
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel

First Posted Date: 2022-03-11

Last Posted Date: 2024-05-17

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 66

Registration Number: NCT05275777

Locations: 🇸🇬
National University Hospital, Singapore, Singapore

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

Phase 1

Recruiting

Conditions: B-cell Lymphoma
Burkitt Lymphoma

Interventions: Drug: Etoposide
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Vincristine
Drug: Prednisone
Drug: Loncastuximab Tesirine 0.075 mg/kg by IV
Drug: Loncastuximab tesirine 0.12 mg/kg by IV
Drug: Loncastuximab tesirine 0.15 mg/kg by IV

First Posted Date: 2022-03-08

Last Posted Date: 2024-06-04

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 33

Registration Number: NCT05270057

Locations: 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 2

Active, not recruiting

Conditions: Liposarcoma, Dedifferentiated

Interventions: Drug: Brigimadlin (BI 907828)
Drug: Doxorubicin

First Posted Date: 2022-02-01

Last Posted Date: 2024-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 401

Registration Number: NCT05218499

Locations: 🇺🇸
City of Hope-Duarte-56419, Duarte, California, United States
🇺🇸
Nebraska Cancer Specialists-Omaha-69502, Omaha, Nebraska, United States
🇦🇺
Prince of Wales Hospital-Randwick-66496, Randwick, New South Wales, Australia

and more 105 locations

Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Nanoxel M
Drug: Taxotere
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2022-01-26

Last Posted Date: 2024-05-17

Lead Sponsor: Samyang Biopharmaceuticals Corporation

Target Recruit Count: 26

Registration Number: NCT05207514

Locations: 🇰🇷
Sevrance Hospital, Seoul, Korea, Republic of

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Epcoritamab
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2022-01-21

Last Posted Date: 2024-12-03

Lead Sponsor: Genmab

Target Recruit Count: 49

Registration Number: NCT05201248

Locations: 🇨🇳
Tianjin Cancer Hospital /ID# 228135, Tianjin, Tianjin, China
🇨🇳
Peking University Third Hospital /ID# 228138, Beijing, Beijing, China
🇨🇳
The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing, China

and more 15 locations

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Non Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Lenalidomide
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone (or equivalent)

First Posted Date: 2022-01-20

Last Posted Date: 2022-03-11

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 36

Registration Number: NCT05200312

Locations: 🇨🇳
First affiliation hospital of nanjing medical university, Nanjing, Jiangsu, China
🇨🇳
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China